Sharon P. Wilczynski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sharon P. Wilczynski has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Albert Y. Ko
Department of Surgery, VAGLAHS/David Geffen School of Medicine at UCLA, Los Angeles, California
81 shared publications - Bhavani Shankara Gowda
Department of Surgery, VAGLAHS/David Geffen School of Medicine at UCLA, Los Angeles, California
81 shared publications - Daniel Sanghoon Shin
University of California Los Angeles Medical Center, Los Angeles, CA
81 shared publications - Eri S. Srivatsan
Department of Surgery VAGLAHS/David Geffen School of Medicine at UCLA Los Angeles California USA
81 shared publications - Ibraheem Ali
Department of Louise M. Darling Biomedical Library and The Institute for Quantitative and Computational Biology, UCLA, Los Angeles, California
81 shared publications - Isabelle Y. Liu
Department of Surgery, VAGLAHS/David Geffen School of Medicine at UCLA, Los Angeles, California
81 shared publications
Latest Publications
- Open Access
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 8 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
Absence of T allele expression is associated with absence of multimeric protein formation and mRNA instability. A, Western blot analysis of ME180, HeLa, HT3, and SiHa cells post actinomycin D treatment (10 µg/mL, 8 µmol/L) shows enhanced γH2AX expression in all four cell lines pointing to positive drug effect. Higher expression of 60 kD gigaxonin protein is seen in ME180, HT3, and SiHa cells in comparison with that of HeLa cells. Multimeric forms of the protein are absent in SiHa cells pointing to the association between loss of T allelic expression and absence of multimeric protein formation. B, RNA stability assays show half-life of HeLa cells to be 3.22 hours and that of ME180 and SiHa cell lines to be 5.09 and 7.88 hours, respectively. GAN RNA is more stable in HT3 cells. These results therefore indicate instability of GAN mRNA in HeLa cells showing C allele expression. C, Half-live of p16 (CDKN2A) is 5.49 hours and cyclin D1 mRNA is more stable in HeLa cells, matching the half-lives reported in the literature (34, 35). These results therefore indicate that actinomycin D treatment was effective in the cancer cell lines. D, qRT-PCR studies of ME180 cells transfected with RelA cDNA (3-fold) or treated with TNFα (5-fold after 15 minutes) show activation of NFκB compared with control cDNA or untreated control cells, respectively. There is activation of Snail in RelA transfected cells (2-fold) and in 30 and 60 minutes treatment of TNFα (1.6-fold) confirming transcription activation of Snail by NFκB. The time lag to NFκB may be related to time delay in the activation of NFκB signaling pathway. Downregulation of CDH1 (e-cadherin) and GAN (gigaxonin) coinciding with Snail upregulation points to transcriptional downregulation of these two genes. While inhibition of e-cadherin transcription by Snail is known (58–60), we for the first time show transcriptional regulation of GAN with NFκB activation indicating a feedback regulation. E, A mechanism is proposed where GAN gene exon 8 SNP (T allele) expression is associated with enhanced gigaxonin expression (upward arrow) leading to ubiquitination of NFκB resulting in Snail downregulation, increased expression of e-cadherin and maintenance of epithelial phenotype. Loss of gigaxonin through C allele expression (downward arrow) leads to enhanced NFκB expression, activation of Snail, downregulation of e-cadherin and development of mesenchymal (EMT) phenotype. Our results extend the interrelationship between these genes reported earlier by the other investigators (52–55). → Activation, ┤ Inhibition.
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 8 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
Absence of T allele expression is associated with absence of multimeric protein formation and mRNA instability. A, Western blot analysis of ME180, HeLa, HT3, and SiHa cells post actinomycin D treatment (10 µg/mL, 8 µmol/L) shows enhanced γH2AX expression in all four cell lines pointing to positive drug effect. Higher expression of 60 kD gigaxonin protein is seen in ME180, HT3, and SiHa cells in comparison with that of HeLa cells. Multimeric forms of the protein are absent in SiHa cells pointing to the association between loss of T allelic expression and absence of multimeric protein formation. B, RNA stability assays show half-life of HeLa cells to be 3.22 hours and that of ME180 and SiHa cell lines to be 5.09 and 7.88 hours, respectively. GAN RNA is more stable in HT3 cells. These results therefore indicate instability of GAN mRNA in HeLa cells showing C allele expression. C, Half-live of p16 (CDKN2A) is 5.49 hours and cyclin D1 mRNA is more stable in HeLa cells, matching the half-lives reported in the literature (34, 35). These results therefore indicate that actinomycin D treatment was effective in the cancer cell lines. D, qRT-PCR studies of ME180 cells transfected with RelA cDNA (3-fold) or treated with TNFα (5-fold after 15 minutes) show activation of NFκB compared with control cDNA or untreated control cells, respectively. There is activation of Snail in RelA transfected cells (2-fold) and in 30 and 60 minutes treatment of TNFα (1.6-fold) confirming transcription activation of Snail by NFκB. The time lag to NFκB may be related to time delay in the activation of NFκB signaling pathway. Downregulation of CDH1 (e-cadherin) and GAN (gigaxonin) coinciding with Snail upregulation points to transcriptional downregulation of these two genes. While inhibition of e-cadherin transcription by Snail is known (58–60), we for the first time show transcriptional regulation of GAN with NFκB activation indicating a feedback regulation. E, A mechanism is proposed where GAN gene exon 8 SNP (T allele) expression is associated with enhanced gigaxonin expression (upward arrow) leading to ubiquitination of NFκB resulting in Snail downregulation, increased expression of e-cadherin and maintenance of epithelial phenotype. Loss of gigaxonin through C allele expression (downward arrow) leads to enhanced NFκB expression, activation of Snail, downregulation of e-cadherin and development of mesenchymal (EMT) phenotype. Our results extend the interrelationship between these genes reported earlier by the other investigators (52–55). → Activation, ┤ Inhibition.
- Open Access
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 18 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
E-cadherin and Snail expression in breast and prostate cancer samples
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 18 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
E-cadherin and Snail expression in breast and prostate cancer samples
- Open Access
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
Representative soft agar colonies of ME180, HeLa, and Siha cell lines
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
Representative soft agar colonies of ME180, HeLa, and Siha cell lines
- Open Access
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 16 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
Control, GAN siRNA and GAN overexpression effect on transcription factors in ME180 and HeLa cell lines
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 16 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
Control, GAN siRNA and GAN overexpression effect on transcription factors in ME180 and HeLa cell lines
- Open Access
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
RNA differential expression in mE180 and GAN edited cell lines
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
RNA differential expression in mE180 and GAN edited cell lines
- Open Access
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 19 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
Ubiquitination assay for GAN binding to Snail and NF-kB
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 19 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
Ubiquitination assay for GAN binding to Snail and NF-kB
- Open Access
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
Incucyte live cell assay of cisplatin treated ME180 cells
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
Incucyte live cell assay of cisplatin treated ME180 cells
- Open Access
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
Exon 8 SNP frequency in normal vs tumors
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
Exon 8 SNP frequency in normal vs tumors
- Open Access
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
Synonymous exome SNP and Indel sequences in ME180 and GAN edited cell lines
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
Synonymous exome SNP and Indel sequences in ME180 and GAN edited cell lines
- Open Access
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
FIGURE 3 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
Enhanced in vitro cell growth and higher expression of EMT markers in GAN edited clones. A, Map of the gRNAs used in CRISPR-Cas9 assay. B, TspGW1 digested DNAs of puromycin-resistant clones of gRNAs 2 and 4 transfected ME180 cells show the presence of 287 and 155/132 bp PCR products (T and C alleles, respectively) compared with the presence of 287 bp (T/T alleles) in the parental ME180 cells. C, Representative morphology of GAN edited clones of gRNA4, C4.15.1, 15.3 in comparison with ME180 cells. D, Exon 8 PCR product sequencing shows conversion of T/T with C/C alleles in the GAN edited clone C4.15.1. Sequencing data show exon 8 SNP site containing T allele in ME180 and C allele in both the GAN edited clones C4.15.1 and C4.15.3. E, Western blot data show decreased expression of gigaxonin and e-cadherin in these clones in comparison with ME180 cells. However, there is increased expression of EMT markers, Snail, Twist, and n-cadherin in GAN edited clones. F, Incucyte growth assay shows faster growth of GAN edited clones C4.15.1 and C4.15.3 in comparison with parental ME180 cells. Cisplatin sensitivity is also reduced in these clones.
- 8 March 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFIGURE 3 from Gigaxonin Suppresses Epithelial-to-Mesenchymal Transition of Human Cancer Through Downregulation of Snail
Enhanced in vitro cell growth and higher expression of EMT markers in GAN edited clones. A, Map of the gRNAs used in CRISPR-Cas9 assay. B, TspGW1 digested DNAs of puromycin-resistant clones of gRNAs 2 and 4 transfected ME180 cells show the presence of 287 and 155/132 bp PCR products (T and C alleles, respectively) compared with the presence of 287 bp (T/T alleles) in the parental ME180 cells. C, Representative morphology of GAN edited clones of gRNA4, C4.15.1, 15.3 in comparison with ME180 cells. D, Exon 8 PCR product sequencing shows conversion of T/T with C/C alleles in the GAN edited clone C4.15.1. Sequencing data show exon 8 SNP site containing T allele in ME180 and C allele in both the GAN edited clones C4.15.1 and C4.15.3. E, Western blot data show decreased expression of gigaxonin and e-cadherin in these clones in comparison with ME180 cells. However, there is increased expression of EMT markers, Snail, Twist, and n-cadherin in GAN edited clones. F, Incucyte growth assay shows faster growth of GAN edited clones C4.15.1 and C4.15.3 in comparison with parental ME180 cells. Cisplatin sensitivity is also reduced in these clones.